Home›Trial›NCT06600724
NCT06600724NARECRUITING

Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs

Study Summary

This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).

Conditions
Diabetic Foot UlcerDiabetic FootFoot Ulcer Due to Type 2 Diabetes MellitusFoot Ulcer, DiabeticFoot Ulcer
Interventions / Drugs
Standard of CareEPIEFFECTEPIXPRESS
View on ClinicalTrials.gov ↗
Sponsor
MDXG
MiMedx Group
Regenerative Medicine
D38/100
Study Details
Enrollment170 participants
Primary Completion—
Lead SponsorMiMedx Group, Inc.
Data Retrieved2026-04-11 04:20:58.628844+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 170 participants
Sponsor Catalyst Profile

MiMedx Group (MDXG) is the sponsoring company for this trial. BiotechSign currently grades this company D (38/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

MDXG Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.